XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
SEGMENTS
 9 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
SEGMENTS

11. SEGMENTS

 

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic subsidiary. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

 

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

 

The following tables set forth certain information regarding our segments:

      
   Nine Months Ended December 31,
   2021  2020
Revenues:      
Aethlon  $281,049   $624,871 
ESI   –    – 
Total Revenues  $281,049   $624,871 
           
Operating Losses:          
Aethlon  $(6,614,318)  $(5,610,994)
ESI   (20,869)   (15,931)
Total Operating Loss  $(6,635,187)  $(5,626,925)
           
Net Losses:          
Aethlon  $(6,614,318)  $(5,610,994)
ESI   (20,869)   (15,931)
Net Loss Before Non-Controlling Interests  $(6,635,187)  $(5,626,925)
           
Depreciation and Amortization:          
Aethlon  $98,363   $28,775 
ESI   –    – 
Total Depreciation and Amortization  $98,363   $28,775 
           
Capital Expenditures:          
Aethlon  $136,795   $54,630 
ESI   –    – 
Capital Expenditures  $136,795   $54,630 
           
    December 31, 2021    December 31, 2020 
Cash:          
Aethlon  $20,394,339   $12,131,396 
ESI   197    197 
Total Cash  $20,394,536   $12,131,593 
           
Total Assets:          
Aethlon  $21,916,069   $12,669,552 
ESI   197    197 
Total Assets  $21,916,266   $12,669,749